[{"id":"cbd75b78-349b-4631-8a47-5cdf0f95df72","acronym":"","url":"https://clinicaltrials.gov/study/NCT07113132","created_at":"2025-08-09T14:21:21.716Z","updated_at":"2025-08-09T14:21:21.716Z","phase":"","brief_title":"Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia","source_id_and_acronym":"NCT07113132","lead_sponsor":"Safaa Ali","biomarkers":" SF3B1","pipe":"","alterations":" ","tags":["SF3B1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-08-08"},{"id":"9dace7a4-0aa6-4f4b-ad55-e52edc08eadf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04251078","created_at":"2021-01-18T20:39:29.313Z","updated_at":"2025-02-25T13:40:03.793Z","phase":"","brief_title":"Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples","source_id_and_acronym":"NCT04251078","lead_sponsor":"Josep Carreras Leukaemia Research Institute","biomarkers":" BRAF • SF3B1 • GATA1","pipe":"","alterations":" ","tags":["BRAF • SF3B1 • GATA1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"930271d4-4c89-4b12-9340-38647392d747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732961","created_at":"2023-02-17T15:00:52.691Z","updated_at":"2025-02-25T14:17:40.080Z","phase":"Phase 2","brief_title":"Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms","source_id_and_acronym":"NCT05732961","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"ee309a82-4f0b-426f-a0b1-deeeabf2fd59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04802161","created_at":"2021-03-17T15:57:34.517Z","updated_at":"2025-02-25T16:32:23.537Z","phase":"Phase 2","brief_title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","source_id_and_acronym":"NCT04802161","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2","pipe":" | ","alterations":" Chr del(11q)","tags":["RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"99f4875a-0520-4340-a630-53ddf9fb3ea7","acronym":"PRISMM","url":"https://clinicaltrials.gov/study/NCT04447651","created_at":"2021-01-18T21:24:05.813Z","updated_at":"2025-02-25T14:29:23.488Z","phase":"","brief_title":"Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)","source_id_and_acronym":"NCT04447651 - PRISMM","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" SF3B1 • SRSF2 • U2AF1","pipe":" | ","alterations":" SF3B1 mutation • SRSF2 mutation • U2AF1 mutation","tags":["SF3B1 • SRSF2 • U2AF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation • SRSF2 mutation • U2AF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/17/2020","start_date":" 09/17/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-08-02"},{"id":"711f8265-575f-4a14-bb60-be585609d334","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024994","created_at":"2021-08-27T12:53:02.872Z","updated_at":"2025-02-25T13:35:55.158Z","phase":"Phase 2","brief_title":"A Study of E7820 in People With Bone Marrow (Myeloid) Cancers","source_id_and_acronym":"NCT05024994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation","tags":["FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7820"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-03"},{"id":"b4b55ef9-4653-42bf-95e0-84efd373e033","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891249","created_at":"2023-06-06T14:07:08.438Z","updated_at":"2024-07-02T16:34:26.950Z","phase":"Phase 4","brief_title":"A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) \u0026 Beta-thalassemia (β-Thal) in India","source_id_and_acronym":"NCT05891249","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 04/13/2026","primary_completion_date":" 04/13/2026","study_txt":" Completion: 04/13/2026","study_completion_date":" 04/13/2026","last_update_posted":"2024-06-12"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"f6c20e60-2c54-4ca4-a32a-1818b76a2ae4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03770429","created_at":"2021-01-18T18:39:17.898Z","updated_at":"2025-02-25T15:08:09.884Z","phase":"Phase 1","brief_title":"AZD6738 for Patients With Progressive MDS or CMML","source_id_and_acronym":"NCT03770429","lead_sponsor":"Massachusetts General Hospital","biomarkers":" SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-03-15"},{"id":"15953f0f-132c-44a4-9f39-8d36bdd31ec9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04278768","created_at":"2021-05-11T14:53:15.390Z","updated_at":"2024-07-02T16:35:15.352Z","phase":"Phase 1/2","brief_title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS","source_id_and_acronym":"NCT04278768","lead_sponsor":"Curis, Inc.","biomarkers":" FLT3 • SF3B1 • U2AF1","pipe":" | ","alterations":" FLT3 mutation • SF3B1 mutation • U2AF1 mutation","tags":["FLT3 • SF3B1 • U2AF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • SF3B1 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)"],"overall_status":"Recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-11"},{"id":"1511b518-b2d9-44d0-a52a-ddad9c414044","acronym":"CORONADO CLL","url":"https://clinicaltrials.gov/study/NCT05405309","created_at":"2022-06-06T13:56:17.349Z","updated_at":"2024-07-02T16:35:19.578Z","phase":"Phase 1/2","brief_title":"RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05405309 - CORONADO CLL","lead_sponsor":"University of Utah","biomarkers":" TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation","tags":["TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2024-02-13"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"b5a9bf94-a0bf-4a0f-b85d-89df1fb88d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03204188","created_at":"2021-01-18T15:48:00.906Z","updated_at":"2024-07-02T16:35:27.918Z","phase":"Phase 2","brief_title":"Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03204188","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TP53 • SF3B1","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • SF3B1 mutation","tags":["TP53 • SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-11-28"},{"id":"eecc0761-d3fa-49cf-82cd-389c0096a5df","acronym":"LUSPLUS","url":"https://clinicaltrials.gov/study/NCT05181592","created_at":"2022-01-06T22:53:42.390Z","updated_at":"2025-02-25T14:16:35.136Z","phase":"Phase 3","brief_title":"Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.","source_id_and_acronym":"NCT05181592 - LUSPLUS","lead_sponsor":"GWT-TUD GmbH","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation • Chr del(5q)","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-10-12"},{"id":"0498e653-58b8-4f7a-ba46-3446c5b95b95","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983237","created_at":"2023-08-09T14:09:26.536Z","updated_at":"2024-07-02T16:35:40.277Z","phase":"Phase 1/2","brief_title":"Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma","source_id_and_acronym":"NCT05983237","lead_sponsor":"Jun Guo","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-11"},{"id":"2442f2c8-6bb4-47a1-a6f7-7355ce55c7d0","acronym":"FerMDS","url":"https://clinicaltrials.gov/study/NCT05924074","created_at":"2023-06-29T14:08:58.357Z","updated_at":"2024-07-02T16:35:44.402Z","phase":"","brief_title":"Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)","source_id_and_acronym":"NCT05924074 - FerMDS","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" SF3B1","pipe":"","alterations":" ","tags":["SF3B1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-06-29"},{"id":"5a55c8ba-84c1-4c67-a725-dab20754576f","acronym":"FISiM-Luspa","url":"https://clinicaltrials.gov/study/NCT05520749","created_at":"2022-08-30T20:55:51.039Z","updated_at":"2024-07-02T16:35:55.523Z","phase":"","brief_title":"Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche","source_id_and_acronym":"NCT05520749 - FISiM-Luspa","lead_sponsor":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Completed","enrollment":" Enrollment 215","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2023-02-15"},{"id":"de27d4a7-da28-4adb-9c83-edc82f6ec299","acronym":"MEDALIST","url":"https://clinicaltrials.gov/study/NCT02631070","created_at":"2021-01-18T12:47:39.328Z","updated_at":"2025-02-25T16:15:32.760Z","phase":"Phase 3","brief_title":"A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","source_id_and_acronym":"NCT02631070 - MEDALIST","lead_sponsor":"Celgene","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 02/09/2016","start_date":" 02/09/2016","primary_txt":" Primary completion: 06/18/2019","primary_completion_date":" 06/18/2019","study_txt":" Completion: 11/26/2020","study_completion_date":" 11/26/2020","last_update_posted":"2021-12-17"},{"id":"73e97b9d-0254-43f8-997d-ea880735e4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311815","created_at":"2021-01-18T16:21:28.250Z","updated_at":"2024-07-02T16:36:34.554Z","phase":"","brief_title":"Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.","source_id_and_acronym":"NCT03311815","lead_sponsor":"PETHEMA Foundation","biomarkers":" KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2","pipe":" | ","alterations":" U2AF1 mutation","tags":["KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e U2AF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 900","initiation":"Initiation: 10/06/2017","start_date":" 10/06/2017","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2021-02-16"},{"id":"8e772c5c-efa1-43b0-a436-6535ec330b7b","acronym":"PMF/ET-FLT","url":"https://clinicaltrials.gov/study/NCT03116542","created_at":"2021-01-18T15:21:18.891Z","updated_at":"2024-07-02T16:36:40.562Z","phase":"","brief_title":"18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia","source_id_and_acronym":"NCT03116542 - PMF/ET-FLT","lead_sponsor":"Hamad Medical Corporation","biomarkers":" IDH1 • IDH2 • JAK2 • SF3B1 • ASXL1 • TET2 • SRSF2 • CALR","pipe":"","alterations":" ","tags":["IDH1 • IDH2 • JAK2 • SF3B1 • ASXL1 • TET2 • SRSF2 • CALR"],"overall_status":"Unknown status","enrollment":" Enrollment 21","initiation":"Initiation: 05/07/2017","start_date":" 05/07/2017","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2020-09-29"},{"id":"f887d510-0878-4a46-85d9-281df4450717","acronym":"AMICUS","url":"https://clinicaltrials.gov/study/NCT02804984","created_at":"2021-01-18T13:45:14.737Z","updated_at":"2024-07-02T16:37:08.315Z","phase":"","brief_title":"Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance","source_id_and_acronym":"NCT02804984 - AMICUS","lead_sponsor":"Centre Hospitalier Universitaire, Amiens","biomarkers":" KRAS • IDH1 • IDH2 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • U2AF1 • GATA2 • ZRSR2","pipe":"","alterations":" ","tags":["KRAS • IDH1 • IDH2 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • U2AF1 • GATA2 • ZRSR2"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2018-08-03"}]